ArticleStem cell research2009
Generation of tissue-specific cells from MSC does not require fusion or donor-to-host mitochondrial/membrane transfer.
Article in Stem cell research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Mitochondria Transfer in Mesenchymal Stem Cells: Unraveling the Mechanism and Therapeutic Potential.Current stem cell research & therapy · 2025Review
- Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels.Frontiers in immunology · 2022Article
- Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A.Frontiers in cell and developmental biology · 2021Article
- Gene and Stem Cell Therapies for Fetal Care: A Review.JAMA pediatrics · 2020Review
- Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A.Molecular therapy. Methods & clinical development · 2020Article
- Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery.Molecular therapy. Methods & clinical development · 2020Review
- The hematopoietic system in the context of regenerative medicine.Methods (San Diego, Calif.) · 2016Review
- In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application.Molecular therapy. Methods & clinical development · 2016Review
- Perivascular stromal cells as a potential reservoir of human cytomegalovirus.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2014Article
- Hemophilia A: an ideal disease to correct in utero.Frontiers in pharmacology · 2014Review
- EphB2 isolates a human marrow stromal cell subpopulation with enhanced ability to contribute to the resident intestinal cellular pool.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
- Mesenchymal stem cells contribute to endogenous FVIII:c production.Journal of cellular physiology · 2013Article
- In utero transplantation: Disparate ramifications.World journal of stem cells · 2013Article
- Article
- Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model.Hepatology (Baltimore, Md.) · 2012Article
- Periocular and intra-articular injection of canine adipose-derived mesenchymal stem cells: an in vivo imaging and migration study.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2012Article
- Treatment of Hemophilia A in Utero and Postnatally using Sheep as a Model for Cell and Gene Delivery.Journal of genetic syndromes & gene therapy · 2012Article
- Modulation of human mesenchymal stem cell immunogenicity through forced expression of human cytomegalovirus us proteins.PloS one · 2012Article
- Stem cell therapy: a novel & futuristic treatment modality for disaster injuries.The Indian journal of medical research · 2012Review
- Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC.Experimental hematology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Human mesenchymal stem cells (MSC) hold great promise for cellular replacement therapies. Despite their contributing to phenotypically distinct cells in multiple tissues, controversy remains regarding whether the phenotype switch results from a true differentiation process. Here, we studied the events occurring during the first 120 h after human MSC transplantation into a large animal model. We demonstrate that MSC, shortly after engrafting different tissues, undergo proliferation and rapidly initiate the differentiative process, changing their phenotype into tissue-specific cells. Thus, the final level of tissue-specific cell contribution is not determined solely by the initial level of engraftment of the MSC within that organ, but rather by the proliferative capability of the ensuing tissue-specific cells into which the MSC rapidly differentiate. Furthermore, we show that true differentiation, and not cell fusion or transfer of mitochondria or membrane-derived vesicles between transplanted and resident cells, is the primary mechanism contributing to the change of phenotype of MSC upon transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.